Regeneron Pharmaceuticals v. Fuji Pharma
Patent infringement preliminary injunction case
Withdrawn following a settlement
scroll
Topics
& News
open_in_new
NEW
ABE & PARTNERS has been ranked in Tier 1 for Patent Contentious in Asia IP's Rankings.
open_in_new
NEW
Takanori ABE has been selected as Top 50 IP Experts of Japan 2026 by Asia IP.
open_in_new
NEW
Takanori ABE has been selected as Japan’s Top 100 A-list lawyers by Asia Business Law Journal.
open_in_new
ABE & PARTNERS wins Boutique Law Firm of the Year at ALB Japan Law Awards 2026.
open_in_new
ABE & PARTNERS was selected as Silver by IAM Patent 1000 2026 in the category of Litigation.
open_in_new
ABE & PARTNERS was selected as a finalist for ALB Japan Law Award 2026 in the Eight categories.
Cases
Samsung Bioepis v. Regeneron Pharmaceuticals
Unfair Competition PI Case / Unfair Competition PI appeal case
Dismissal decision / Dismissal decision
Samsung Bioepis v. Bayer Healthcare
Unfair Competition PI Case
Dismissal decision
X v. U.S. Pharmaceutical Company
Patent Opposition
Patent maintained
Japanese Pharmaceutical Company v. Indian Pharmaceutical Company
Trial for Patent Invalidation for vaccine patent
Invalidity decision
Publications
"Reading Stief, Haedicke and Wunsche, with the memory of a decade fought in Germany"
Source : LSIPR
"What happens if you are sued in Tokyo after Pantech v Google?"
Source : WIPR
"Setting the Standard in Life Science and Healthcare Law"
Source : M&A TODAY
"A True Pioneer in Intellectual Property Law: Mr. Takanori ABE’s Empowering Journey"
Source : PRIME VIEW
"Five minutes with…Takanori Abe, Abe & Partners"
Source : Managing Intellectual Property
“International IP
Law Firm of the Year”― ACQ Global Awards
Information
-
＜Caution＞
ABE & PARTNERS has received information that the name of our firm and atrorney from our office have been used to attempt to commit fraud.
If you receive any contact from an unknown person using the name of our office or an attorney from our office, do not respond immediately, but please fully confirm the identity of that person.
In addition, we would greatly appreciate your informing us by using "Contact".